Soluble C-X-C chemokine ligand 16 levels are increased in gout patients

Clinical Biochemistry

Volumn 45, Issue 16-17, 2012, Pages 1368-1373

  Gong, Qi ^a   Wu, Fan ^a   Pan, Xuebo ^a   Yu, Jiawen ^a   Li, Yilan ^a   Lu, Tingting ^a   Li, Xiaokun ^a,b   Lin, Zhuofeng ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

Author keywords

Chronic kidney disease; Gout; Renal function; Soluble C X C chemokine ligand 16

Indexed keywords

C REACTIVE PROTEIN; CXCL16 CHEMOKINE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GOUT; HUMAN; KIDNEY FUNCTION; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA;

AGED; BLOOD UREA NITROGEN; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINES, CXC; CREATININE; FEMALE; GOUT; HUMANS; KIDNEY; LEUKOCYTES, MONONUCLEAR; LIPIDS; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, SCAVENGER; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER;

EID: 84868302510     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.05.014     Document Type: Article

References (28)

1. Terkeltaub R., Zachariae C., Santoro D., Martin J., Peveri P., Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991, 34:894-903.
2. Chen L., Guo L., Tian J., He H., Marinova E., Zhang P., et al. Overexpression of CXC chemokine ligand 14 exacerbates collagen-induced arthritis. J Immunol 2010, 184:4455-4459.
3. van Lieshout A.W., Fransen J., Flendrie M., Eijsbouts A.M., van den Hoogen F.H., van Riel P.L., et al. Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. Ann Rheum Dis 2007, 66:1334-1338.
4. Proost P., Vynckier A.K., Mahieu F., Put W., Grillet B., Struyf S., et al. Microbial Toll-like receptor ligands differentially regulate CXCL10/IP-10 expression in fibroblasts and mononuclear leukocytes in synergy with IFN-gamma and provide a mechanism for enhanced synovial chemokine levels in septic arthritis. Eur J Immunol 2003, 33:3146-3153.
5. Kasama T., Strieter R.M., Lukacs N.W., Lincoln P.M., Burdick M.D., Kunkel S.L. Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995, 95:2868-2876.
6. Hosaka S., Akahoshi T., Wada C., Kondo H. Expression of the chemokine superfamily in rheumatoid arthritis. Clin Exp Immunol 1994, 97:451-457.
7. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000, 1:298-304.
8. van d, V, van Lieshout A.W., Toonen L.W., Slöetjes A.W., van den Berg W.B., Figdor C.G., et al. Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum 2005, 52:1381-1391.
9. Ruth J.H., Haas C.S., Park C.C., Amin M.A., Martinez R.J., Haines G.K., et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006, 54:765-778.
10. Tabata S., Kadowaki N., Kitawaki T., Shimaoka T., Yonehara S., Yoshie O., et al. Distribution and kinetics of SR-PSOX/CXCL16 and CXCR6 expression on human dendritic cell subsets and CD4+ T cells. J Leukoc Biol 2005, 77:777-786.
11. Wuttge D.M., Zhou X., Sheikine Y., Wågsäter D., Stemme V., Hedin U., et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004, 24:750-755.
12. Chandrasekar B., Bysani S., Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004, 279:3188-3196.
13. Gutwein P., bdel-Bakky M.S., Schramme A., Doberstein K., Kämpfer-Kolb N., Amann K., et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol 2009, 174:2061-2072.
14. Watanabe K., Penfold M.E., Matsuda A., Ohyanagi N., Kaneko K., Miyabe Y., et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum 2010, 62(11):3211-3220.
15. Ruth J.H., Arendt M.D., Amin M.A., Ahmed S., Marotte H., Rabquer B.J., et al. Expression and function of CXCL16 in a novel model of gout. Arthritis Rheum 2010, 62:2536-2544.
16. So A. Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 2008, 10:221.
17. Becker M.A., Schumacher H.R., Wortmann R.L., MacDonald P.A., Palo W.A., Eustace D., et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005, 52:916-923.
18. Bertsias G.K., Ioannidis J.P., Aringer M., Bollen E., Bombardieri S., Bruce I.N., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69(12):2074-2082.
19. Zhang W., Doherty M., Pascual E., Bardin T., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301-1311.
20. Zhang W., Doherty M., Bardin T., Pascual E., Barskova V., Conaghan P., et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.
21. Wallace S.L., Robinson H., Masi A.T., Decker J.L., McCarty D.J., Yu T.F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977, 20:895-900.
22. Zhang X., Yeung D.C., Karpisek M., Stejskal D., Zhou Z.G., Liu F., et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008, 57:1246-1253.
23. Gutwein P., Abdel-Bakky M.S., Schramme A., Doberstein K., Kämpfer-Kolb N., Amann K., et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol. 2009, 174(6):2061-2072.
24. van Lieshout A.W., van d, V, Toonen L.W., van Helden S.F., Figdor C.G., van Riel P.L., et al. Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1036-1043.
25. Lin Z., Gong Q., Zhou Z., Zhang W., Liao S., Liu Y., et al. Increased plasma CXCL16 levels in patients with chronic kidney diseases. Eur J Clin Invest 2011, 41:836-845.
26. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18:2600-2608.
27. Coresh J., Selvin E., Stevens L.A., Manzi J., Kusek J.W., Eggers P., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
28. Nanki T., Shimaoka T., Hayashida K., Taniguchi K., Yonehara S., Miyasaka N. Pathogenic role of the CXCL16-CXCR6 pathway in rheumatoid arthritis. Arthritis Rheum 2005, 52:3004-3014.